Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

115.64 +1.87 (+1.64%)
Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Novartis Dumps Another Bispecific Candidate From Xencor Deal
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... 
Via Benzinga
The Old Lady Of Threadneedle Street
US markets are up on better jobs growth reported for October today. 
Via Talk Markets
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Earnings Scheduled For October 26, 2021
Companies Reporting Before The Bell • Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million. • Aarons (NYSE:AAN)... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Why Did Deciphera Stock Plunged 70% Today?
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in... 
Via Benzinga
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Novartis To Offload Its Stake Back To Roche For $20.7B
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... 
Via Benzinga
Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad
The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally... 
Via Benzinga
FDA Approves Novartis' Scemblix In Two Chronic Myeloid Leukemia Settings
The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications. The FDA granted... 
Via Benzinga
Exposures Product Safety
Tuesday Market Coverage
Thermo Electron fell on the publication of its social responsibility report today. 
Via Talk Markets
Novartis (NVS) Q3 2021 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Boosts Guidance For These Key Drugs After Their Bang-Up Quarter
Novartis stock inched higher Tuesday after the company reported a mixed third quarter, but increased guidance for two drugs. 
Via Investor's Business Daily
Novartis: Q3 Earnings Insights
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 26, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook
Novartis AG (NYSE: NVS) reported that its Q3 net income climbed 43% to $2.76 billion. EPS reached $1.23, up 45% Y/Y. Earnings: The Company posted a core EPS of $1.71,... 
Via Benzinga
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
A Preview Of Novartis's Earnings
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2021-10-26. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Price To Earnings Ratio Insights For Novartis
In the current market session, Novartis Inc. (NYSE:NVS) is trading at $84.51, after a 0.19% decrease. However, over the past month, the stock increased by 1.91%, and... 
Via Benzinga
Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines
Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19... 
Via Benzinga
Exposures COVID-19
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
Great Place to Work® Announces the World’s Best Workplaces™ 2021
Great Place to Work® Announces the World’s Best Workplaces™ 2021 
Via News Direct
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based... 
Via Benzinga
3 No-Brainer Stocks to Buy Right Now
These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term. 
Via The Motley Fool
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.